203 related articles for article (PubMed ID: 9819673)
21. High-affinity anti-DNA antibody parallels clinical course of immunoadsorption therapy for systemic lupus erythematosus.
Funauchi M; Ikoma S; Enomoto H; Ohno M; Kinoshita K; Horiuchi A; Kurata N
Intern Med; 1996 May; 35(5):367-72. PubMed ID: 8797048
[TBL] [Abstract][Full Text] [Related]
22. Crossroads of the effects of cyclophosphamide pulse therapy for lupus nephritis--experience of 11 cases.
Funauchi M; Ikoma S; Sugiyama M; Yu H; Ohno M; Kinoshita K; Hamada K; Kanamaru A
J Clin Lab Immunol; 1998; 50(2):45-54. PubMed ID: 10470622
[TBL] [Abstract][Full Text] [Related]
23. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years.
Moroni G; Doria A; Mosca M; Alberighi OD; Ferraccioli G; Todesco S; Manno C; Altieri P; Ferrara R; Greco S; Ponticelli C
Clin J Am Soc Nephrol; 2006 Sep; 1(5):925-32. PubMed ID: 17699309
[TBL] [Abstract][Full Text] [Related]
24. The efficacy of intravenous pulse cyclophosphamide in the treatment of severe lupus nephritis in children.
Tangnararatchakit K; Tapaneya-Olarn C; Tapaneya-Olarn W
J Med Assoc Thai; 1999 Nov; 82 Suppl 1():S104-10. PubMed ID: 10730528
[TBL] [Abstract][Full Text] [Related]
25. Pentoxifylline in the treatment of refractory nephrotic syndrome secondary to lupus nephritis.
Galindo-Rodríguez G; Bustamante R; Esquivel-Nava G; Salazar-Exaire D; Vela-Ojeda J; Vadillo-Buenfil M; Aviña-Zubieta JA
J Rheumatol; 2003 Nov; 30(11):2382-4. PubMed ID: 14677181
[TBL] [Abstract][Full Text] [Related]
26. [Plasmapheresis in a case of necessary discontinuation of cyclophosphamide in the treatment of severe lupus nephritis].
Saracyn M; Korsak J; Wańkowicz Z
Pol Merkur Lekarski; 2004 Aug; 17(98):162-4. PubMed ID: 15603328
[TBL] [Abstract][Full Text] [Related]
27. [Lupus nephritis as a factor of atherosclerosis risk in patients with systemic lupus erythematosus].
Serikova SIu; Kozlovskaia NL; Shilov EM
Ter Arkh; 2008; 80(6):52-8. PubMed ID: 18655477
[TBL] [Abstract][Full Text] [Related]
28. [Intermittent intravenous cyclophosphamide application in patients with systemic lupus erythematosus].
Anić B; Crkvencić N; Mayer M; Bosnić D; Sentić M; Markeljević J; Cikes N
Lijec Vjesn; 1999; 121(9-10):283-8. PubMed ID: 19658369
[TBL] [Abstract][Full Text] [Related]
29. Clinical efficacy of centrifugal-membranous hybrid double filtration plasmapheresis and membranous double filtration plasmapheresis on severe lupus nephritis.
Dong J; Huang L; Li C; Wu B; Yang X; Ge Y
Lupus; 2023 Aug; 32(9):1066-1074. PubMed ID: 37487569
[TBL] [Abstract][Full Text] [Related]
30. [Cyclophosphamide-induced lupus flare in diffuse proliferative lupus nephropathy].
Heras M; Saiz A; Fernández-Reyes MJ; Sánchez R; Zurita P; Urrego C
Nefrologia; 2011; 31(2):231-3. PubMed ID: 21461001
[No Abstract] [Full Text] [Related]
31. Therapy of lupus nephritis. A two-year prospective study.
Doria A; Piccoli A; Vesco P; Vaccaro E; Marson P; De Silvestro G; Ossi E; Gambari P
Ann Med Interne (Paris); 1994; 145(5):307-11. PubMed ID: 7985937
[TBL] [Abstract][Full Text] [Related]
32. Predictive factors of clinical outcome in patients with diffuse proliferative lupus nephritis treated early by intravenous methylprednisolone pulse therapy.
Kanno A; Hotta O; Yusa N; Taguma Y
Ren Fail; 2007; 29(1):41-7. PubMed ID: 17365909
[TBL] [Abstract][Full Text] [Related]
33. Accelerated recovery from nephrotic syndrome with acute renal failure by double filtration plasmapheresis in a patient with lupus podocytopathy.
Iwazu Y; Akimoto T; Izawa S; Inoue M; Muto S; Ando Y; Iwazu K; Fukushima N; Yumura W; Kusano E
Clin Exp Nephrol; 2012 Jun; 16(3):485-9. PubMed ID: 22350466
[TBL] [Abstract][Full Text] [Related]
34. Comparison of double filtration plasmapheresis with immunoadsorption therapy in patients with anti-glomerular basement membrane nephritis.
Zhang YY; Tang Z; Chen DM; Gong DH; Ji DX; Liu ZH
BMC Nephrol; 2014 Aug; 15():128. PubMed ID: 25086644
[TBL] [Abstract][Full Text] [Related]
35. Clinical predictors of recovery and complications in the management of recent-onset renal failure in lupus nephritis: a Chinese experience.
Liang L; Yang X; Xu H; Zhan Z; Ye Y; Yu X; Chen W
J Rheumatol; 2004 Apr; 31(4):701-6. PubMed ID: 15088294
[TBL] [Abstract][Full Text] [Related]
36. Effective treatment of young patients with pediatric-onset, long-standing lupus nephritis with tacrolimus given as a single daily dose: an open-label pilot study.
Tanaka H; Oki E; Tsugawa K; Nonaka K; Suzuki K; Ito E
Lupus; 2007; 16(11):896-900. PubMed ID: 17971363
[TBL] [Abstract][Full Text] [Related]
37. Idiotypic vaccination with a murine anti-dsDNA antibody: phase I study in patients with nonactive systemic lupus erythematosus with nephritis.
Spertini F; Leimgruber A; Morel B; Khazaeli MB; Yamamoto K; Dayer JM; Weisbart RH; Lee ML
J Rheumatol; 1999 Dec; 26(12):2602-8. PubMed ID: 10606369
[TBL] [Abstract][Full Text] [Related]
38. Severe pemphigus vulgaris: successful combination therapy of plasmapheresis followed by intravenous high-dose immunoglobulin to prevent rebound increase in pathogenic IgG.
Aoyama Y; Nagasawa C; Nagai M; Kitajima Y
Eur J Dermatol; 2008; 18(5):557-60. PubMed ID: 18693160
[TBL] [Abstract][Full Text] [Related]
39. Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis.
Danieli MG; Palmieri C; Salvi A; Refe MC; Strusi AS; Danieli G
J Clin Apher; 2002; 17(2):72-7. PubMed ID: 12210709
[TBL] [Abstract][Full Text] [Related]
40. Double-filtration plasmapheresis.
Tanabe K
Transplantation; 2007 Dec; 84(12 Suppl):S30-2. PubMed ID: 18162985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
